With business expansion a key priority for companies globally, many are focused on identifying and entering new growth markets.
This section of International Labmate highlights successful companies establishing operations or partnerships beyond their home markets, showcasing export
To appear in our next issue, send your Business and Financial News stories to
gwyneth@intlabmate.com by Gwyneth Astles
opportunities and inspiring others to explore international business potential.
Strategic investment strengthens global molecular biology partnership
Integra Biosciences has acquired shares in CleanNA, deepening their long-term collaboration and expanding CleanNA’s global presence in molecular biology.
CleanNA, a Netherlands-based specialist in magnetic bead-based DNA/RNA extraction kits, complements Integra’s liquid handling and automation portfolio. The partnership initially focused on private-label distribution of SPRI MAGFLO™ beads for NGS size selection and PCR purification. Integra’s investment now positions the companies to expand integrated solutions for NGS library preparation and automated workflows.
Urs Hartmann, CEO of Integra Biosciences, said: “CleanNA’s innovative capabilities align perfectly with our vision for efficient, automated lab solutions. This investment underlines our commitment to long-term growth and supporting CleanNA in developing new applications and reaching broader markets.”
Glenn Nohar, CEO of CleanNA, added: “The strategic alignment and shared mission with Integra make this an exciting step for growth. Their global network enables us to bring our magnetic bead technology to more researchers worldwide.”
By joining forces, the two companies now offer a comprehensive range of bead-based solutions, from
Acquisition strengthens early-stage drug development
Symeres, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO), has acquired DGr Pharma, a consultancy specialised in early-stage drug development and regulatory strategy. This strategic move strengthens Symeres’ integrated services, enhancing its ability to accelerate IND-enabling processes for biopharma clients across Europe and beyond.
Urs Hartmann, CEO at Integra Biosciences AG, Glenn Nohar, CEO at CleanNA BV, and Adrian Oehler, CEO at Integra Holding AG.
reagents and consumables to automation modules, strengthening their position in the molecular biology market.
More information online:
ilmt.co/PL/nvML and
ilmt.co/PL/32JB 65853pr@reply-direct.com
Founded in 2018, DGr Pharma brings deep expertise in preclinical and clinical regulatory planning, quality assurance, and regulatory submissions for small and large molecules, including antibodies, ADCs, and oligonucleotides. By combining Symeres’ existing CRDMO infrastructure with DGr Pharma’s regulatory know-how, the partnership offers a more seamless, end-to-end path from discovery to early clinical development.
Guillaume Jetten, CEO of Symeres, commented: “Acquiring DGr Pharma allows us to deliver a fully integrated development solution, enhancing regulatory support and scientifi c depth for our clients. This strengthens Symeres’ position as a preferred partner for innovative biopharma companies.”
Partnership to drive cell and gene therapy growth in Southeast Asia
eXmoor Pharma, a global CDMO with deep expertise in cell and gene therapies (CGTs), has partnered with Siam Bioscience, a leading biopharmaceutical company in ASEAN, to establish a regional hub for CGT development and manufacturing.
The collaboration aims to accelerate access to advanced therapies across Southeast Asia by combining eXmoor’s technical know-how with Siam Bioscience’s regional infrastructure and market insight. The new centre in Bangkok will offer end-to-end services, from process and analytical development to GMP-compliant clinical and commercial manufacturing, supporting both local innovation and international programmes.
Cell and gene therapies represent the next frontier in medicine, offering potentially curative treatments for conditions such as cancer and rare genetic disorders. However, producing these therapies requires precise, reproducible, and traceable processes. The partnership addresses these challenges while creating a platform for international collaboration, bringing global therapies closer to patients in the region.
Angela Osborne, Executive Chair of eXmoor Pharma, said: “This partnership positions Thailand and Southeast Asia at the forefront of CGT innovation. By combining local leadership with global expertise, we can bring life-changing therapies to patients faster and more effi ciently.”
Songpon Deechongkit, CEC at Siam Bioscience, added: “Our joint CGT centre will strengthen translational research and practical commercialisation in the region, supporting both established and emerging therapies while adhering to international standards.”
With Southeast Asia emerging as a hub for advanced biotherapeutics, this strategic partnership not only enhances regional capability but also creates signifi cant opportunities for global developers seeking faster, locally compliant routes to market.
More information online:
ilmt.co/PL/jYp8 65847pr@reply-direct.com
Kees Groen, Founder and CEO of DGr Pharma, added: “Joining Symeres opens up new opportunities to scale our expertise and broaden the impact we deliver to clients. Together, we can accelerate early-stage development while maintaining our commitment to quality and scientifi c rigor.”
Supported by Keensight Capital, the acquisition underscores a shared vision of expanding capabilities in high-value drug classes while reinforcing Symeres’ role in the global biopharma ecosystem.
More information online:
ilmt.co/PL/BZwR 65876pr@reply-direct.com
Looking to grow your laboratory business internationally?
Whether you’re selling laboratory products or services and seeking new markets, or looking for local distributors and agents to represent your brand — our market-leading publication International Labmate can help you connect with the right audience.
Email:
info@intlabmate.com
Business
Opportunities
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
